| Theme | Prescription of Therapeutics and Monitoring for the Dialysis Patients | |
|---|---|---|
| Title | TDM of antibiotics | |
| Publish Date | 1999/11 | |
| Author | Hiroshi Tanaka | Department of Urology, Ohno Memorial Hospital |
| [ Summary ] | Hemodialysis patients may easily become infected. Earlier chemotherapy is recommended for these patients, because their conditions will become more serious when treatment for infection is delayed. A drug, which has a low possibility for promoting resistant bacteria, and which easily shifts its focus to the infected organ or location of infection, should be selected for patients with the possibility of contracting infectious bacteria diseases. Intravenous infusion is possible for hemodialysis patients, through the blood line. Serum concentrations of dialyzable drugs must be monitored during and after hemodialysis treatment. Serum concentrations are changed according to hemodialysis dosage and patient body weight. TDM is necessary during various types of blood purification. When weekly serum concentrations of drugs are simulated, the pharmacokinetic parameters, both during and without hemodialysis treatment must be used. Results should be checked by actually monitoring serum concentrations. Residual renal functioning should be protected, and the side effects of the antibiotics must be prevented through TDM. Systems, which can show medication planning for antibiotics, using the simulation of pharmacokinetics, are expected to be developed in the near future, when the information about the drugs, the patients, and hemodialysis treatment is given. |
|